<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336062</url>
  </required_header>
  <id_info>
    <org_study_id>NAB-PTX-GC</org_study_id>
    <nct_id>NCT01336062</nct_id>
  </id_info>
  <brief_title>Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients</brief_title>
  <official_title>Phase Ib/IIa, Two-stage Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer have poor prognosis and majority of patients resistant to 5-FU/DDP based&#xD;
      first-line chemotherapy in China. There was no recommended second-line chemotherapy for&#xD;
      advanced gastric cancer. Taxane is promising in gastric cancer. Nanoparticle Albumin-Bound&#xD;
      Paclitaxel (Abraxane，ABI-007) has good convenience to use and been approved in breast cancer&#xD;
      in many countries. The investigator then initiated a prospective phase Ib/IIa clinical trial&#xD;
      with nab-paclitaxel plus TS-1 as the second-line treatment in advanced gastric cancer to&#xD;
      observe the safety and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a two-stage design. Stage 1&#xD;
&#xD;
      The investigator should evaluate two recommend dose and tolerability of nab-paclitaxel plus&#xD;
      S-1 after one course of treatment as 3+1 design:&#xD;
&#xD;
      nab-paclitaxel should be given intravenously on days 1 and 8 at a dose as follows, Treatment&#xD;
      should be repeated every 3 weeks: Treatment arm A：125 mg /m2; Treatment arm B：100 mg /m2;&#xD;
      Treatment arm C: 80 mg /m2; S-1 should be given orally twice a day as follows for 14&#xD;
      consecutive days, followed by a 1-week rest. Treatment should be repeated every 3 weeks. BSA&#xD;
      &lt; 1.5 m2，40mg，bid;BSA ≥ 1.5 m2，50mg，bid.&#xD;
&#xD;
      The investigator should determine whether to continue the original regimen; compare the&#xD;
      safety and pharmacokinetic results with original profile of combination therapy to select the&#xD;
      best therapy programs (RD, recommended dose).&#xD;
&#xD;
      Stage 2 According to two-stage design (Simon,1989), re-entry subjects to the recommended dose&#xD;
      group to a total of 25 valid cases. If 11 patients achieve response, then enter the second&#xD;
      phase of total 66 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>during the treatment in the hosptital,an expected average of 3 weeks</time_frame>
    <description>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>the follow-up visit of PFS will be performed every 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival of participants</measure>
    <time_frame>2 years</time_frame>
    <description>OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarkers</measure>
    <time_frame>6 weeks</time_frame>
    <description>If the tumour samples available, to identify the molecular characteristics(such as SPARK,ABCG2,β-Tubulin III,PDGFRA,etc) of responding tumours by immunohistochemical, FISH, genomic and proteomic analysis; To study biomarkers expression before and during therapy and establish correlations with clinical outcome and toxicity;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Nanoparticle Albumin-Bound Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanoparticle Albumin-Bound Paclitaxel</intervention_name>
    <description>this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;</description>
    <arm_group_label>Nanoparticle Albumin-Bound Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form&#xD;
&#xD;
          2. Age 18-75 years;&#xD;
&#xD;
          3. Histologically or cytologically confirmed gastric cancer;&#xD;
&#xD;
          4. Advanced or recurrent, metastatic disease;&#xD;
&#xD;
          5. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1;&#xD;
&#xD;
          6. Life expectancy of at least 12 weeks;&#xD;
&#xD;
          7. At least have one measurable disease(according to RECIST, Response Evaluation Criteria&#xD;
             in Solid Tumors )&#xD;
&#xD;
          8. Subjects who have received one prior regimen for gastric carcinoma and developed&#xD;
             disease progression or recurrence within 6 months after the end of systemic adjuvant&#xD;
             treatment. The regimen must have contained fluorouracil(e.g. 5-FU,capecitabine) and/or&#xD;
             cisplatin;&#xD;
&#xD;
          9. Haematopoietic status:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1.5 x 109/L,&#xD;
&#xD;
               -  Platelet count &gt; 90 x 109/L,&#xD;
&#xD;
               -  Hemoglobin at least 9 g/dl,&#xD;
&#xD;
         10. Hepatic status:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal (ULN),&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times ULN(no liver metastasis), ≤5 times ULN(with liver&#xD;
                  metastasis)&#xD;
&#xD;
         11. Renal status:&#xD;
&#xD;
             - Creatinine ≤1.5 times ULN or calculated creatinine clearance, using the&#xD;
             Cockcroft-Gault formula, ≥40 mL/min;&#xD;
&#xD;
         12. Able to swallow and retain oral medication；without malabsorption syndrome, or disease&#xD;
             significantly affecting gastrointestinal function, such as ulcerative colitis and&#xD;
             Crohn's disease;&#xD;
&#xD;
         13. Cardiovascular: Baseline LVEF 50% measured by echocardiography (ECHO) ;&#xD;
&#xD;
         14. Negative serum pregnancy test (For women of childbearing potential);Fertile patients&#xD;
             must use effective contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any prior treatment including taxane or S-1;&#xD;
&#xD;
          2. Concurrent systemic anti-cancer therapy (immunotherapy, biologic therapy, hormone&#xD;
             therapy, etc ); received treatment with an investigational agent or participation in&#xD;
             another therapeutic clinical trial within 4 weeks;&#xD;
&#xD;
          3. Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities&#xD;
             greater than grade 2; peripheral neuropathy of grade 2 or greater&#xD;
&#xD;
          4. Symptomatic brain metastasis;&#xD;
&#xD;
          5. Known history of uncontrolled or symptomatic angina, clinically significant&#xD;
             arrhythmias, congestive heart failure, uncontrolled hypertension (≥ 180/110), unstable&#xD;
             diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen;&#xD;
&#xD;
          6. History of other malignancy. However, subjects with a past or current history of&#xD;
             completely resected basal and squamous cell carcinoma of the skin or successfully&#xD;
             treated in situ carcinoma of the cervix are eligible&#xD;
&#xD;
          7. Dementia, altered mental status, or any psychiatric condition that would prevent the&#xD;
             understanding or rendering of ICF;&#xD;
&#xD;
          8. Active or uncontrolled infection;&#xD;
&#xD;
          9. Concurrent treatment with an investigational agent or participation in another&#xD;
             therapeutic clinical trial;&#xD;
&#xD;
         10. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lin Shen</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>PRO.</investigator_title>
  </responsible_party>
  <keyword>advanced</keyword>
  <keyword>resistant to prior chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

